The T. Rowe Price Health Sciences strategy is among the better options available given its strong investment resources, research depth, and framework.
T. Rowe Price Health Sciences PRHSX
Morningstar’s Analysis PRHSX
Will PRHSX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 50.0
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Aggregate Miscellaneous Equity | 9.56 | 1.4 Bil | — |
UnitedHealth Group Inc | 8.08 | 1.2 Bil | Healthcare |
Eli Lilly and Co | 8.04 | 1.2 Bil | Healthcare |
Thermo Fisher Scientific Inc | 4.73 | 695.5 Mil | Healthcare |
Intuitive Surgical Inc | 3.82 | 562.2 Mil | Healthcare |
Elevance Health Inc | 3.54 | 520.1 Mil | Healthcare |
Merck & Co Inc | 3.51 | 516.2 Mil | Healthcare |
Stryker Corp | 3.24 | 477.1 Mil | Healthcare |
Danaher Corp | 2.77 | 407.2 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 2.73 | 401.2 Mil | Healthcare |